Microvascular Therapeutics, LLC
Microvascular Therapeutics (MVT) is a pioneering biotech company specializing in ultrasound contrast agents and theranostics, with a focus on developing innovative formulations for medical imaging and therapy. Led by a team with over 50 years of combined experience, MVT aims to advance the field of microbubble and nanodroplet technology for applications in cardiovascular, neurological, and oncological disorders, striving for accelerated approval pathways and groundbreaking clinical solutions.
Industries
Nr. of Employees
small (1-50)
Microvascular Therapeutics, LLC
Patents
Products
Ultrasound microbubble contrast agent for echocardiography (clinical lead)
A lipid-based microbubble formulation developed for echocardiographic contrast imaging and potential image-guided therapy; advanced through early-phase clinical studies under an accelerated regulatory pathway.
Phase-shift microbubble therapeutics for thrombus dissolution (preclinical)
Phase-shift microbubble formulations designed for ultrasound-enhanced sonothrombolysis to treat vascular thrombosis and microvascular obstruction.
Targeted imaging agents for oncology and ocular indications (preclinical)
Targeted microbubble agents designed to improve detection and differentiation of small tumors (pancreatic, breast) and to diagnose ocular inflammation, with potential for drug delivery applications.
Ultrasound microbubble contrast agent for echocardiography (clinical lead)
A lipid-based microbubble formulation developed for echocardiographic contrast imaging and potential image-guided therapy; advanced through early-phase clinical studies under an accelerated regulatory pathway.
Phase-shift microbubble therapeutics for thrombus dissolution (preclinical)
Phase-shift microbubble formulations designed for ultrasound-enhanced sonothrombolysis to treat vascular thrombosis and microvascular obstruction.
Targeted imaging agents for oncology and ocular indications (preclinical)
Targeted microbubble agents designed to improve detection and differentiation of small tumors (pancreatic, breast) and to diagnose ocular inflammation, with potential for drug delivery applications.
Services
Process development, scale-up, technology transfer, and GMP production of injectable lipid-based perfluorocarbon micro- and nanoemulsions.
Design and conduct of in vivo efficacy studies, imaging protocols, and analytical assessment for ultrasound-based diagnostic and therapeutic agents.
Partnership formation, licensing of technology from academic institutions, and joint development agreements to advance imaging and therapeutic ultrasound products.
Process development, scale-up, technology transfer, and GMP production of injectable lipid-based perfluorocarbon micro- and nanoemulsions.
Design and conduct of in vivo efficacy studies, imaging protocols, and analytical assessment for ultrasound-based diagnostic and therapeutic agents.
Partnership formation, licensing of technology from academic institutions, and joint development agreements to advance imaging and therapeutic ultrasound products.
Expertise Areas
- Ultrasound contrast agent development
- Theranostics and sonothrombolysis
- Molecular ultrasound imaging
- Microbubble and nanoemulsion formulation
Key Technologies
- Lipid-shelled microbubbles
- Phase-shift microbubbles / perfluorocarbon nanoemulsions
- Contrast-enhanced ultrasound (CEUS)
- Ultrasound-targeted microbubble cavitation (UTMC)
News & Updates
Dr. Evan Unger to participate in a discussion on commercializing SBIR/STTR technologies at the 2025 BIO International Convention.
MVT announced successful completion of clinical trials for its lead ultrasound contrast agent candidate, CardiSon (MVT-100).
Partnership to advance microbubble and ultrasound theranostics.
Strategic collaboration to develop new treatment options for vascular thrombosis.
Enrollment completed for Phase 2 clinical trial of MVT-100.
Recognition for Dr. Unger's contributions to contrast media research.
Dr. Evan Unger to participate in a discussion on commercializing SBIR/STTR technologies at the 2025 BIO International Convention.
MVT announced successful completion of clinical trials for its lead ultrasound contrast agent candidate, CardiSon (MVT-100).
Partnership to advance microbubble and ultrasound theranostics.
Strategic collaboration to develop new treatment options for vascular thrombosis.
Enrollment completed for Phase 2 clinical trial of MVT-100.
Recognition for Dr. Unger's contributions to contrast media research.